Marked Individual Variation in Isoflavone Metabolism After a Soy Challenge Can Modulate the Skeletal Effect of Isoflavones in Premenopausal Women.
10.3346/jkms.2009.24.5.867
- Author:
Ho Seok KWAK
1
;
So Young PARK
;
Mi Gyeong KIM
;
Chang Hoon YIM
;
Hyun Koo YOON
;
Ki Ok HAN
Author Information
1. Division of Endocrinology, Department of Internal Medicine, Cheil General Hospital and Women's Healthcare Center, Kwandong University School of Medicine, Seoul, Korea. kiok.han@cgh.co.kr
- Publication Type:Original Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
- Keywords:
Premenopausal Women;
Isoflavones;
Equol;
Genistein;
Bone Turnover;
Estrogen Antagonists
- MeSH:
Adult;
Amino Acids/urine;
Bone and Bones/*drug effects/metabolism;
Double-Blind Method;
Estrogen Antagonists/*pharmacokinetics/pharmacology/urine;
Female;
Humans;
Isoflavones/*pharmacokinetics/pharmacology/urine;
Middle Aged;
Osteocalcin/blood;
*Premenopause
- From:Journal of Korean Medical Science
2009;24(5):867-873
- CountryRepublic of Korea
- Language:English
-
Abstract:
Soy-isoflavones may act as estrogenic agonists or antagonists depending on the endogenous hormone status. These clinical effects can be exerted variably in individuals by the metabolic ability to produce a more potent metabolite than precursors. The objective of this randomized, double-blind, placebo-controlled study was to investigate the skeletal effect of isoflavones according to their metabolic variability in premenopausal women. Volunteers were randomly assigned to receive either soy-extract isoflavones (n=32) or lactose (n=21) once a day for three menstrual cycles. After intervention, the urinary excretions of isoflavones and their metabolites were significantly higher in the soy group than in the placebo group and showed a large inter-individual variation. Women in the soy group were divided into subgroups according to their ability to excrete more potent metabolites. Serum osteocalcin and urine deoxypyridinoline showed a tendency to increase after a challenge in equol high-excretors. Serum osteocalcin concentration in the genistein high-excretors increased significantly after a challenge (P=0.04) but did not increase in either the placebo or genistein low-excretors. An estrogenic antagonistic effect of isoflavones on bone turnover was observed in premenopausal women who are able to produce more potent metabolites.
